Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Curtails Development Deals For Pulmonary Drug, HIV Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Altana says it will continue to develop Daxas for chronic obstructive pulmonary disease and asthma independently after Pfizer pulls out of the collaboration. One-year data failed to meet one primary endpoint. Pfizer also ends a development pact with Shionogi for the HIV/AIDS agent capravirine.

You may also be interested in...

Altana Pulls EU Application For Daxas

Altana has withdrawn the European marketing authorization application for its pulmonary agent Daxas (roflumilast), the firm announced Nov. 15

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts